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Abstract 
Palmar-plantar erythrodysesthesia (PPE), also called hand-foot syndrome, is a relatively 
common dermatologic toxic reaction associated with cytotoxic chemotherapy that can 
limit the use of such drugs. Definitive prevention and treatment strategies for PPE have 
not yet been established. We present a patient with recurrent ovarian cancer developing 
severe hand-foot syndrome after treatment with pegylated liposomal doxorubicin. A 
review of the relevant literature concerning pathophysiology, preventive measures and 
management of PPE is given. Electronic search was conducted using the Medline 
database for English-language records. The search terms used were ‘palmar-plantar 
erythrodysesthesia’, ‘hand-foot syndrome’, ‘pegylated liposomal doxorubicin’ and ‘acral 
erythema’. 
Case Report 
A 69-year-old woman diagnosed with clinical stage IV platinum-refractory ovarian carcinoma 
received pegylated liposomal doxorubicin (PLD) treatment at a dose of 50 mg/m
2 every 4 weeks. After 
three treatments the patient had mild erythema and swelling and tingling of the hands, which did not 
interfere with her daily activities. This was evaluated as grade 1 palmar-plantar erythrodysesthesia 
(PPE), so-called hand-foot syndrome. The patient was advised to apply cream and to avoid extreme 
temperatures and excessive pressure or friction to the skin. Dose modification of PLD was not indicated 
(table 1). After the fourth treatment the patient developed blistering, ulcerations with infectious 
complications and pain and was severely disabled, consistent with grade 4 PPE. The lesions were located 
on both palms and soles (fig. 1) and required immediate hospitalization. The patient received treatment 
with oral pyridoxine, oral and topical steroids and pain killers, as well as locally applicated creams and 
emollients. After 1 week the ulcers were healing and the patient was discharged. Two weeks later, the 
skin lesions were completely healed while light erythema and tingling in the hands persisted. The 
chemotherapy treatment has since been reduced in dose, as recommended in table 1.  
Case Rep Oncol 2011;4:229–235 
DOI: 10.1159/000327767 
Published online: 
April 11, 2011 







Electronic searches were conducted using the Medline database for English-language records. The 
search terms used were ‘palmar-plantar erythrodysesthesia’, ‘hand-foot syndrome’, ‘pegylated liposomal 
doxorubicin’ and ‘acral erythema’. 
Discussion 
A number of cytotoxic drugs have been reported to be linked to hand-foot syndrome, 
but it is most frequently associated with 5-fluorouracil, PLD, docetaxel, capecitabine, 
vinorelbine, gemcitabine and sorafenib [1]. PLD is a form of doxorubicin encapsulated 
within pegylated liposomes. This changes its biodistribution and prolongs drug half-life, 
which results in the decrease of toxic effects, especially cardiotoxicity [2]. PLD is 
approved for the treatment of patients with advanced ovarian cancer, metastatic breast 
cancer and soft tissue sarcomas. 
The rate of hand-foot syndrome associated with PLD is increased compared to patients 
receiving conventional doxorubicin. The incidence of PLD-associated hand and foot 
syndrome reported by several authors is approximately 50% for patients with any grade of 
PPE, and approximately 20% for patients with grade 3 and 4 PPE [2, 3], for a PLD dose of 
50 mg/m
2 every 4 weeks. The available evidence indicates, however, that a dose of 40 
mg/m
2 every 4 weeks is at present considered equally effective and less toxic, and is 
therefore the preferred dosage [4]. 
PPE presents as a painful erythematous rash, often associated with edema, located on 
the palms, fingers and soles, occurring 2–12 days after administration of chemotherapy. It 
is preceded by dysesthesia. The rash may become bullous and ulcerative, associated with 
severe pain and interference with daily activities (table 1). 
Histologic features of PPE are non-specific and based on a small number of patients. 
They include vacuolar degeneration of the basal cell layer, mild spongiosis, keratinocytes 
necrosis, papillary dermal edema, lymphohistiocytic infiltrates and partial separation of 
the epidermis from the dermis. 
Perivascular infiltrates composed of lymphocytes and eosinophils are often seen in the 
dermis. There may also be evidence of eccrine squamous syringometaplasia or 
neutrophilic eccrine hidradenitis. Skin biopsies from 2 patients with PLD-associated PPE 
showed vacuolar degeneration of the basal layer of the epidermis, along with mild 
perivascular lymphocytic infiltration of the dermis, hyperkeratosis and apoptotic 
keratinocytes. Clinical, electrophysiologic and biopsy data suggest that small-fibre 
neuropathy may be the cause of pain and dysesthesia [5]. 
The pathophysiological mechanism of PPE is an area of active investigation. Factors 
involved could be rapid cell division in palms and soles, gravitational forces, vascular 
anatomy peculiar to these areas and temperature gradients in the distal extremities, as 
well as increased drug concentration in the eccrine glands of the palms and soles. 
Research has uncovered the likely mechanism for PPE in patients treated with PLD. 
PLD is known to preferentially localize in both tumour and skin, with pre-clinical testing 
using murine models finding higher PLD levels in paws than in skin [6]. In another study, 
PLD fluorescence was quantitatively evaluated in humans using a dermatological laser  
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scanning microscope. Three hours after PLD administration, fluorescence was observed 
in the uppermost part of the skin of the flexor forearm, palm, sole, axilla and forehead of a 
male patient [7]. A fluorescence signal was also detected, deep in the sweat glands and 
orifices of the palms, suggesting that the drug is transported by sweat to the skin’s surface, 
perhaps facilitated by the hydrophilic coating of the liposome. Once on the surface of the 
skin, the drug was observed to be carried in sweat and to penetrate into the stratum 
corneum, which may serve as a reservoir, allowing penetration of the drug into the deeper 
layers of skin. Once penetration occurs, free radicals are formed and react with epidermal 
cells, leading to PPE. The palmar and plantar areas are characterized by high numbers of 
eccrine sweat glands that continuously secrete fluid and are thus most at risk for PPE. 
Occurrence of PPE has been shown to be related to dose and prolonged drug exposure 
during continuous intravenous infusion, daily ingestion, as well as liposomal 
encapsulation of PLD which prolongs drug half-life. The use of cooling mechanisms, 
higher number of PLD cycles, and occurrence of mucositis, neutropenia, and peripheral 
neuropathy are possible predictors of PPE [8].  
Even though severe grade 4 symptoms are not common and PPE has not been 
described to be a life-threatening condition, it can be disabling and impair the quality of 
life of the patient. Hackbarth et al. [9] analyzed the impact of dermatological toxicities on 
patients’ quality of life. Their results showed that more than two thirds of patients 
developed a dermatological reaction (62.9%) and felt significantly limited in pursuing 
their daily activities. PPE appeared to have a significant effect on overall health, as 
approximately 90% of patients with grade 3 PPE felt severely limited by this and 
approximately 70% even felt restricted in doing their work or other daily activities. 
These data suggest that PPE as a side effect of chemotherapy constitutes an important 
factor limiting quality of life of patients, as is also shown in the present case.  
The most effective management of PPE is treatment interruption, lengthening the 
interval between drug administrations or dose reduction of PLD. This normally leads to a 
rapid subsidence of symptoms, which usually resolve within 1–2 weeks. 
The product information for PLD recommends dose modification in accordance with 
the clinical presentation and grade of PPE, which is shown in table 1. 
Different measures have been suggested to prevent PPE symptoms, such as avoidance 
of friction, excessive pressure to the skin and extreme temperatures, and the application 
of creams [1, 4]. A variety of creams and emollients have been shown not only to ease the 
symptoms of grade 1 PPE but even to prevent symptom development if used early 
enough. However, the efficacy of these measures has not been reported in controlled trials 
and emphasis is placed on the management of symptoms as they manifest and progress. 
Agents like dimethylsulfoxide, oral and topical steroids seem to be effective for PPE 
symptoms of various grades, but none of them has been evaluated by randomized clinical 
trials [1, 3, 4]. 
There are numerous case reports of the successful use of oral pyridoxine (vitamin B6) 
at doses up to 800 mg daily for the management of PPE caused by a wide range of agents. 
In a case report, pyridoxine 100 mg three times daily was used successfully to treat PLD-
associated PPE [10]. In contrast to these case reports, a large prospective, randomized 
double-blind study evaluating the efficacy of pyridoxine in the prevention of  
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capecitabine-associated PPE found no benefit [11]. Pyridoxine cream has been used alone 
or in combination with pyridoxine tablets for the management of PPE, but data are 
limited [1]. Pre-clinical data on animals support the efficacy of pyridoxine on PLD-
associated PPE [12]. The use of pyridoxine for PLD-associated PPE is not well supported 
and it cannot be recommended outside the research setting. 
Regional cooling via ice packs to the wrists and ankles during treatment with PLD has 
been suggested to be effective [13]. The theory behind this is that cooling results in 
vasoconstriction and therefore less drug circulation to the distal extremities, which may 
lead to less drug extravasation into the surrounding tissue, with reduced cutaneous 
toxicity as a result. The lower temperatures may also play a role in stabilizing the 
liposomal configuration of doxorubicin, leading to a reduced concentration of 
uncapsulated doxorubicin.  
Mangili et al. [13] report the results of a prospective, observational and non-
randomized study of patients treated with PLD for gynecologic cancers. The patients 
received application of ice packs on the extremities and icicles during PLD infusion. They 
observed a statistically significant reduction in PPE incidence and severity. Their data 
suggest that a prolonged administration interval and the association with other agents do 
not reduce skin toxicity while patients receiving PLD at a lower dosage experienced hand-
foot syndrome less frequently. The use of regional cooling further reduces symptoms. 
Although its efficacy needs to be proved prospectively in a controlled and randomized 
trial, the authors suggest that the introduction of the regional cooling strategy, together 
with correct instructions to patients regarding behavioral rules, could play a fundamental 
role in reducing the incidence of PPE. 
While regional cooling appears promising for the prevention of PPE, data are not 
sufficient to support the routine use in clinical practice. According to the consensus-based 
recommendations of an international panel of experts, published in 2008, dose intensity 
modification is currently the most effective and best-documented approach to the 
prevention of hand-foot syndrome [14]. At a PLD dose intensity not exceeding 10 
mg/m
2/week (typically administered as 40 mg/m
2 every 4 weeks), hand-foot syndrome is 
usually mild and easily managed and grade 4 PPE should not occur. While large, phase III 
randomized controlled clinical trials have not evaluated the effectiveness of dose intensity 
modification in the treatment of PPE, the available data and clinical experience suggest 
that this intervention most reproducibly impacts the natural history and severity of PLD-
induced hand-foot syndrome. Therefore, patient education regarding the early signs and 
symptoms of PPE and the importance of prevention and early intervention using 
supportive care approaches are essential components in the prevention and management 
of PPE. Other strategies should be avoided outside the research setting, as their efficacy 
has not been demonstrated in phase III studies. Further research should be focused on 
conducting phase III research on PPE prevention and treatment. For example, 
pyridoxine, regional cooling and systemic corticosteroids have only limited data to 
support their use and cannot be recommended without the support of phase III data.  
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Patients with recurrent ovarian cancer have a remote probability of cure, therefore 
palliation of symptoms, preservation of quality of life and prolongation of progression-
free survival are the primary treatment goals. An improved safety profile of PLD may 
result in an improved quality of life for patients with advanced ovarian cancer. 
Hand and foot syndrome is a common skin toxicity in patients treated with PLD. 
Although the incidence of a severe grade of PPE is low, it can have a significant influence 
on a patient’s quality of life and abilities. This needs to be taken into consideration when 
giving PLD treatment and modifying the dose. Preventive and treatment-accompanying 
measures may be advisable. The efficacy of these measures still needs to be assessed in 




Table 1. Toxicity grades of PPE and dose modification guidelines for PLD 
Grade   Clinical symptoms    Dose modification 
1  Mild erythema, edema, or desquamation not 
interfering with normal activities 
  None, unless patient has experienced previous 
grade 3–4 toxicity. If so, delay up to 2 weeks and 
decrease dose by 25%. Return to original dose 
interval.  
2  Erythema, edema, or desquamation 
complicating, but not precluding normal 
activities; blisters/ulcers <2 cm in diameter 
  Delay up to 2 weeks or until resolved to grade 0–
1. If there is no resolution after 2 weeks, PLD 
should be discontinued. 
3  Blistering/ulceration, or edema interfering with 
normal activities; cannot wear regular clothing 
  Delay up to 2 weeks or until resolved to grade 0–
1. Decrease dose by 25% and return to original 
dose interval. If there is no resolution after 2 
weeks, PLD should be discontinued. 
4  Infectious complications, bed 
ridden/hospitalized  
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Fig. 1. Palmar-plantar erythrodysesthesia: blistering/ulceration of hands and feet interfering with 
normal activities after treatment with pegylated liposomal doxorubicin. 
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